DOI: 10.12890/2026_006759
Golimumab-associated myocarditis with progressive eosinophilia after route switch in rheumatoid arthritis
Authors
nawras.ibrahim@hcahealthcare.com
Keywords
Golimumab, rheumatoid arthritis, TNF-α inhibitors, eosinophilic myocarditisAbstract
Introduction: Tumour necrosis factor-alpha (TNF-alpha) inhibitors are cornerstone therapies in rheumatoid arthritis (RA) and generally reduce cardiovascular events. Drug-induced myocarditis associated with TNF-alpha inhibitors is not well-established in pharmacovigilance databases.
Case description: A 51-year-old male with seropositive RA receiving intravenous golimumab presented with acute chest pain, dyspnoea, and left arm numbness without viral prodrome. He had been switched from subcutaneous to intravenous golimumab 6 months prior, producing a 14-fold increase in peak serum concentration. High-sensitivity troponin I peaked at 32,419 ng/l with mildly reduced left ventricular ejection fraction (45–49%) and global hypokinesis. Coronary angiography revealed non-obstructive arteries. Comprehensive viral serology was negative for acute infection. Inflammatory markers were normal. Progressive eosinophilia developed during hospitalization (0.12 to 0.54 ×103/µl). Cardiac magnetic resonance imaging was unavailable at our institution. Despite not initiating prescribed sacubitril/valsartan (continuing only metoprolol), repeat echocardiography at 4 weeks demonstrated complete normalization of left ventricular function; coinciding with near-complete drug elimination. Golimumab was permanently discontinued.
Conclusion: This case meets criteria for clinically suspected myocarditis per the 2024 American College of Cardiology Expert Consensus Decision Pathway. The absence of viral prodrome, negative viral serology, progressive eosinophilia, normal inflammatory markers, and complete functional recovery paralleling drug elimination support drug-induced hypersensitivity myocarditis. Causality assessment yields “probable” by both the World Health Organization - Uppsala Monitoring Centre system and the Naranjo algorithm (score 6 to 8). This case contributes to the limited literature on TNF-alpha inhibitor cardiotoxicity and emphasizes the need for continued pharmacovigilance.
References
- Xiao R, Tang P, Zhou J, Zheng W, Cao Y, Zhu Y, et al. Safety of TNF-alpha inhibitors therapy in patients with rheumatoid arthritis: an umbrella review. EClinicalMedicine 2025;88:103488. doi: 10.1016/j.eclinm.2025.103488
- Nguyen LS, Cooper LT, Kerneis M, Funck-Brentano C, Silvain J, Brechot N, et al. Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database. Nat Commun 2022;13:25. doi: 10.1038/s41467-021-27631-8
- Zhong Y, Li Z, Tao J, Yuan J, Fu Z. Drug-induced myocarditis: a real-world pharmacovigilance study using the FDA adverse event reporting system database. Expert Opin Drug Saf 2026;25:123-130. doi: 10.1080/14740338.2024.2416933
- Zhuang Y, Xu Z, Frederick B, de Vries DE, Ford JA, Keen M, et al. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study. Clin Ther 2012;34:77-90. doi: 10.1016/j.clinthera.2011.11.015
- Writing Committee; Drazner MH, Bozkurt B, Cooper LT, Aggarwal NR, Basso C, et al. 2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2025;85:391-431. doi: 10.1016/j.jacc.2024.10.080
- Ammirati E, Palazzini M, Lehtonen J, Potena L, Mäyränpää MI, Ragback J, et al. Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis. Circulation 2026;153:634-652. doi: 10.1161/CIRCULATIONAHA.125.074797
- Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245. doi: 10.1038/clpt.1981.154
- Ganatra S, Barac A, Armenian S, Cambareri C, Denlinger CS, Dent SF, et al. Diagnosis and Management of Cardiovascular Adverse Effects of Targeted Oncology Therapies: Bruton’s Tyrosine Kinase, Immune Checkpoint, and Vascular Endothelial Growth Factor Inhibitors: 2025 ACC Concise Clinical Guidance: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2026;87:654-682. doi: 10.1016/j.jacc.2025.10.018
- Herrmann J, Barac A, Carver J, Cheng RK, Daniele A, Dent S, et al. Immune Checkpoint Inhibitor-Associated Cardiovascular Toxic Effects: International Cardio-Oncology Society Position Statement. JAMA Oncol 2026;12:90-99. doi: 10.1001/jamaoncol.2025.4543
- Rolski F, Tkacz K, Weglarczyk K, Kwiatkowski G, Pelczar P, Jazwa-Kusior A, Bar A, et al. TNF-alpha protects from exacerbated myocarditis and cardiac death by suppressing expansion of activated heart-reactive CD4+ T cells. Cardiovasc Res 2024;120:82-94. doi: 10.1093/cvr/cvad158
